[1]吴方强,许夕海.2014~2018年我院耐碳青霉烯类肺炎克雷伯菌分布特点及感染患者的临床特点[J].医学信息,2019,32(24):28-31.[doi:10.3969/j.issn.1006-1959.2019.24.010]
　WU Fang-qiang,XU Xi-hai.Distribution Characteristics of Carbapenem-resistant Klebsiella Pneumoniae in our Hospital from 2014 to 2018 and Clinical Characteristics of Infected Patients[J].Medical Information,2019,32(24):28-31.[doi:10.3969/j.issn.1006-1959.2019.24.010]
点击复制

2014~2018年我院耐碳青霉烯类肺炎克雷伯菌分布特点及感染患者的临床特点()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年24期
页码:
28-31
栏目:
论著
出版日期:
2019-12-15

文章信息/Info

Title:
Distribution Characteristics of Carbapenem-resistant Klebsiella Pneumoniae in our Hospital from 2014 to 2018 and Clinical Characteristics of Infected Patients
文章编号:
1006-1959（2019）24-0028-04
作者:
吴方强; 许夕海
（安徽医科大学第一附属医院感染科，安徽 合肥 230022）
Author(s):
WU Fang-qiang; XU Xi-hai
(Department of Infectious Diseases,the First Affiliated Hospital of Anhui Medical University, Hefei 230022,Anhui,China)
关键词:
耐碳青霉烯类肺炎克雷伯菌; 耐药性; 抗菌药物; 预后因素
Keywords:
Carbapenem-resistant Klebsiella pneumoniae; Drug resistance; Antibacterials;  Prognostic factors
分类号:
R446.5
DOI:
10.3969/j.issn.1006-1959.2019.24.010
文献标志码:
A
摘要:
目的 调查某三甲医院近5年耐碳青霉烯类肺炎克雷伯菌的检出情况、感染患者的临床特点，为临床诊疗提供依据。方法收集2014年1月~2018年12月该院临床分离的肺炎克雷伯菌菌株，分析耐碳青霉烯类肺炎克雷伯菌检出率、标本来源分布、科室分布、耐药情况及预后因素。结果 共检出耐碳青霉烯类肺炎克雷伯菌690株，检出率为14.29%；2018年耐碳青霉烯类肺炎克雷伯菌检出率高于2014~2016年，差异有统计学意义（P＜0.05）；标本来源前5位分别为痰、中段尿、血、切口分泌物、导管，标本科室前5位分别是ICU、呼吸科、泌尿外科、烧伤科、神经外科。16种抗生素药敏检测中，CRKP对15种抗生素耐药率超过50%，耐碳青霉烯类肺炎克雷伯菌对复方新明、米诺环素、替加环素、多粘菌素耐药率相对较低，分别为46.91%、31.86%、10.73%、10.10%。治疗无效患者及治疗有效患者在合并基础病≥3种、患有糖尿病、患有恶性肿瘤、入住ICU、机械通气、保留导尿、其他侵袭性操作、混合感染间比较，差异有统计学意义（P＜0.05）；治疗无效患者及治疗有效患者在性别、吸烟、饮酒、心血管疾病、神经系统疾病、血液病、慢性肺病、慢性肝肾功能不全、近期大手术、既往多次住院或本次就诊前已住院间比较，差异无统计学意义（P＞0.05）。结论 耐碳青霉烯类肺炎克雷伯菌感染呈逐年上升趋势，以ICU中耐青霉烯类肺炎克雷伯菌感染患者最多。临床应针对其可能的预后因素，采取有效、可行的诊治和防控措施预防与减少耐碳青霉烯类肺炎克雷伯菌感染发生几率。
Abstract:
Objective To investigate the detection of carbapenem-resistant Klebsiella pneumoniae and clinical characteristics of infected patients in a top three hospital in the past 5 years, and to provide evidence for clinical diagnosis and treatment. Methods The clinical isolates of Klebsiella pneumoniae isolates from January 2014 to December 2018 were collected, and the detection rate of carbapenem-resistant pneumoniae pneumoniae, specimen source distribution, department distribution, drug resistance, and Prognostic factors. Results A total of 690 carbapenem-resistant Klebsiella pneumoniae strains were detected, with a detection rate of 14.29%. The detection rate of carbapenem-resistant Klebsiella pneumoniae in 2018 was higher than that in 2014~2016,the difference was statistically significant (P<0.05); the top 5 sources of specimens were sputum, middle urine, blood, and incision Secretions, catheters, and top 5 undergraduate departments are ICU, Respiratory, Urology, Burns, and Neurosurgery. Among 16 antibiotics, CRKP is more than 50% resistant to 15 antibiotics. Carbapenem-resistant Klebsiella is resistant to compound Xinming, minocycline, tigecycline, and polymyxin The drug resistance rates were relatively low, which were 46.91%, 31.86%, 10.73%, and 10.10%, respectively. There were statistically significant differences between patients who failed to treat and patients who had responded to treatment with a combination of ≥3 basic diseases, there were significant differences between patients with diabetes, malignant tumors, admission to the ICU, mechanical ventilation, retention of urinary catheterization, other invasive procedures, and mixed infections (P<0.05). Patients who failed treatment and patients who were effective in treatment there was no significant difference in smoking, drinking, cardiovascular disease, nervous system disease, blood disease, chronic lung disease, chronic liver and kidney insufficiency, recent major surgery, multiple previous hospitalizations, or hospitalizations before this visit (P＞0.05). Conclusion Carbapenem-resistant Klebsiella pneumoniae infection has an upper-body trend year by year. The number of patients with penicillin-resistant Klebsiella pneumoniae infection in ICU is the highest. Clinically, according to its possible prognostic factors, effective and feasible diagnosis and treatment and prevention and control measures should be taken to prevent and reduce the incidence of carbapenem-resistant Klebsiella infection.

参考文献/References:

[1]Onori R,Gaiarsa S,Comandatore F,et al.Tracking Nosocomial Klebsiella pneumoniae Infections and Outbreaks by Whole-Genome Analysis:Small-Scale Italian Scenario within a Single Hospital[J].J Clin Microbiol,2015,53(9):2861-2868.[2]Zhou Y,Wang X,Shen J,et al.Endogenous Endophthalmitis Caused by Carbapenem-Resistant Hypervirulent Klebsiella Pneumoniae:A Case Report and Literature Review[J].Ocul Immunol Inflamm,2018:1-6.[3]Guducuoglu H,Gursoy NC,Yakupogullari Y,et al.Hospital Outbreak of a Colistin-Resistant, NDM-1- and OXA-48-Producing Klebsiella pneumoniae:High Mortality from Pandrug Resistance[J].Microb Drug Resist,2018,24(7):966-972.[4]薛娟,谢敏,周婷.耐碳青霉烯类肺炎克雷伯菌感染患者的全因死亡率分析[J].中国临床药理学杂志,2018,34(18):2220-2223.[5]Del Chierico F,Cardile S,Pietrobattista A,et al.Liver Transplantation and Gut Microbiota Profiling in a Child Colonized by a Multi-Drug Resistant Klebsiella pneumoniae:A New Approach to Move from Antibiotic to "Eubiotic" Control of Microbial Resistance[J].Int J Mol Sci,2018,19(5):E1280.[6]Pouch SM,Satlin MJ.Carbapenem-resistant Enterobacteriaceae in special populations:Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies[J].Virulence,2017,8(4):391-402.[7]张国兵,毛小红,吴志强,等.肺炎克雷伯菌耐药与抗菌药物使用强度的相关性分析[J].中华医院感染学杂志,2017,27(11):2427-2429,2452.[8]Gao B,Li X,Yang F,et al.Molecular Epidemiology and Risk Factors of Ventilator-Associated Pneumonia Infection Caused by Carbapenem-Resistant Enterobacteriaceae[J].Front Pharmacol,2019(10）:262.[9]Liu P,Li X,Luo M,et al.Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Infection:A Meta-Analysis[J].Microb Drug Resist,2018,24(2):190-198.[10]Priyendu A,Ahmed Z,Varma M,et al.Comparison of Direct Hospitalization Costs and Length of Stay In Carbapenem Resistant Versus Carbapenem Sensitive Klebsiella Pneumoniae Infections In A Tertiary Care Hospital[J].Value in Health,2015,18(7):A581.[11]Wang X,Wang Q,Cao B,et al.Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant Enterobacteriaceae Bacteremia[J].Antimicrob Agents Chemother,2019,63(1):e01511-e01518.[12]张思兵,杜明梅,闫中强,等.基于信息化手段多学科防控耐碳青霉烯类肺炎克雷伯菌的效果分析[J].中华医院感染学杂志,2018,28(10):1569-1573.

相似文献/References:

[1]李淑惠.鲍曼不动杆菌临床分布及耐药性分析[J].医学信息,2018,31(03):165.[doi:10.3969/j.issn.1006-1959.2018.03.061]
　LI Shu-hui.Clinical Distribution and Drug Resistance of Acinetobacter Baumannii[J].Medical Information,2018,31(24):165.[doi:10.3969/j.issn.1006-1959.2018.03.061]
[2]张丽琴,刘 婷,刘 聪,等.赣南地区临床分离菌耐药性变迁及多重耐药菌的流行变化[J].医学信息,2018,31(05):123.[doi:10.3969/j.issn.1006-1959.2018.05.043]
　ZHANG Li-qin,LIU Ting,LIU Cong,et al.Changes of Drug Resistance of Clinical Isolates and Epidemic Changes of Multidrug-resistant Bacteria in Southern Guizhou[J].Medical Information,2018,31(24):123.[doi:10.3969/j.issn.1006-1959.2018.05.043]
[3]雷 敏.不孕不育患者解脲脲支原体培养及耐药性分析[J].医学信息,2018,31(06):156.[doi:10.3969/j.issn.1006-1959.2018.06.055]
　LEI Min.Analysis of Culture and Drug Resistance of Ureaplasma Urealyticum in Infertility Patients[J].Medical Information,2018,31(24):156.[doi:10.3969/j.issn.1006-1959.2018.06.055]
[4]曾 江,邹 燕,刘 滨.耐甲氧西林金黄色葡萄球菌的临床分布及耐药性分析[J].医学信息,2019,32(02):148.[doi:10.3969/j.issn.1006-1959.2019.02.043]
　ZENG Jiang,ZOU Yan,LIU Bin.Clinical Distribution and Drug Resistance Analysis of Methicillin-resistant Staphylococcus Aureus[J].Medical Information,2019,32(24):148.[doi:10.3969/j.issn.1006-1959.2019.02.043]
[5]高程凤,孙 蕊.新生儿败血症致病菌分布及耐药性分析[J].医学信息,2018,31(17):116.[doi:10.3969/j.issn.1006-1959.2018.17.035]
　GAO Cheng-feng,SUN Rui.Distribution and Drug Resistance of Pathogenic Bacteria in Neonatal Septicemia[J].Medical Information,2018,31(24):116.[doi:10.3969/j.issn.1006-1959.2018.17.035]
[6]张 美,王 欢,冯利芬.南京市江宁医院2015年~2017年血培养阳性病原菌分布及耐药性分析[J].医学信息,2018,31(20):108.[doi:10.3969/j.issn.1006-1959.2018.20.032]
　ZHANG Mei,WANG Huan,FENG Li-fen.Analysis of Distribution and Drug Resistance of Blood Culture Positive Pathogens in Jiangning Hospital of Nanjing from 2015 to 2017[J].Medical Information,2018,31(24):108.[doi:10.3969/j.issn.1006-1959.2018.20.032]
[7]彭 杰,张 琴.儿童呼吸内科下呼吸道分离菌分布及药敏分析[J].医学信息,2019,32(03):134.[doi:10.3969/j.issn.1006-1959.2019.03.043]
　PENG Jie,ZHANG Qin.Distribution and Drug Sensitivity Analysis of Lower Respiratory Tract Isolates inChildren's Respiratory Medicine[J].Medical Information,2019,32(24):134.[doi:10.3969/j.issn.1006-1959.2019.03.043]
[8]于文清.下呼吸道感染病原菌分布及耐药性分析[J].医学信息,2018,31(24):74.[doi:10.3969/j.issn.1006-1959.2018.24.019]
　YU Wen-qing.Analysis of Distribution and Drug Resistance of Pathogenic Bacteria in Lower Respiratory Tract Infection[J].Medical Information,2018,31(24):74.[doi:10.3969/j.issn.1006-1959.2018.24.019]
[9]李佳颖,李春霖,王玉莹,等.鲍曼不动杆菌的单药治疗及其联合使用的研究[J].医学信息,2019,32(05):48.[doi:10.3969/j.issn.1006-1959.2019.05.016]
　LI Jia-ying,LI Chun-lin,WANG Yu-ying,et al.Monotherapy of Acinetobacter Baumannii and Its Combined Use[J].Medical Information,2019,32(24):48.[doi:10.3969/j.issn.1006-1959.2019.05.016]
[10]何 静.上皮性卵巢癌化学治疗的研究[J].医学信息,2019,32(18):24.[doi:10.3969/j.issn.1006-1959.2019.18.009]
　HE Jing.Chemotherapy of Epithelial Ovarian Cancer[J].Medical Information,2019,32(24):24.[doi:10.3969/j.issn.1006-1959.2019.18.009]

更新日期/Last Update: 2019-12-15